Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

University of Oxford and Serum Institute of India Agree Licence to Advance the Next-Generation Multi-Stage Malaria Vaccine Candidate Component R78C

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, which has been developed by the Draper Lab in the Department of Paediatrics, and is based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.

Major technological advance reveals how mutations in a tiny non-coding gene cause multiple neuro-developmental disorders

Researchers from the University of Oxford and the Francis Crick Institute, in collaboration with international partners, have made major advances in understanding how mutations in a single non-coding gene contribute to neurodevelopmental disorders affecting thousands of people worldwide.

Magdalen College lit up for Rare Disease Day

Magdalen College Chapel was lit up in the colours of Rare Disease Day last week, as part of the global Chain of Lights initiative.

World's first Phase II Nipah virus vaccine trial launch

The University of Oxford has launched the world’s first Phase II clinical trial of a Nipah virus vaccine candidate.

Major investment puts UK universities at the forefront of groundbreaking lymph node research

Three UK universities have been granted over £1.7m by the Medical Research Council (MRC) to establish a network of lymph node research centres across the UK. The novel LEGACY IIII Network (Lymph nodE single cell Genomics AnCestrY immunity, infection, inflammation and immunisation) will be co-led by the Universities of Oxford, Cardiff and Newcastle and will establish ten specialist lymph node research centres across the country.

The Kaiya Foundation to fund Leukaemia Research at University of Oxford

The Kaiya Foundation has awarded one of its first major research grants, which will fund pioneering research into the fundamental cause of a high-risk leukaemia. The grant is being made to Dr Emily Neil and Professor Anindita Roy from the Childhood Leukaemia Research Group, based at the University of Oxford, in the hope that their discoveries will transform treatment approaches for sufferers through personalised medicine.

New jab protects babies from serious lung infection, study shows

Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, research suggests.

Construction begins on state-of-the-art research facility

The University of Oxford held a groundbreaking ceremony on Tuesday 24 June to celebrate the start of construction of the Cyrus Poonawalla Vaccines Research Building. The ceremony marks a significant milestone in Oxford’s mission to counter and constrain global health threats.

Oxford vaccine against deadly Nipah virus granted EMA PRIME designation for the first time

The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe’s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.

Study identifies key immune structures in the gut that may drive coeliac disease

Researchers in Oxford have found structures of immune cells in the gut that may be driving the response to gluten in people with coeliac disease and could provide a target for future therapies.

Spotlight on Magdalen College Chapel for Rare Disease Day

The chapel facade of Magdalen College was lit up ahead of the commemoration of Rare Disease Day (RDD) which was celebrated on Friday 28th February 2025. The celebration is held on 29th February in a leap year as it is the rarest day in the year.

Oxford and partners lead on two new MRC Centres to create cutting-edge gene therapies

Oxford University researchers are to lead and co-lead on two MRC research centres, which are being launched to develop new advanced treatments for currently untreatable diseases.

Athena Swan Gold award

The Department of Paediatrics has been awarded the Athena Swan Gold award for its commitment to advancing gender equality in higher education. Established in 2005 to encourage and recognise commitment to advancing the careers of women in science, technology, engineering, maths and medicine (STEMM) employment, the Charter is now used across the globe to address gender equality and barriers to progression that affect women.

New research identifies autoimmunity against a key anti-inflammatory regulator in inflammatory bowel disease

A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.

Research shows early life immunity increases HIV cure/remission in male infants

New research published by scientists at the University of Oxford, the University of KwaZulu-Natal and the Africa Health Research Institute in South Africa, and the Ragon Institute of Mass General, MIT and Harvard, USA, shows that male infants are more likely to achieve HIV cure/remission than females.

How the Information Security Office and the National Cyber Security Centre keeps Oxford's research secure post-pandemic

Oxford University's Information Security Office (InfoSec) invited the NCSC to Oxford to thank them for the work they did that kept Oxford’s vaccine research secure.

Oxford University professors on the record with their contribution to the fight against cancer for this World Cancer Day

This World Cancer Day, four Principal Investigators from the University of Oxford, including Andi Roy, Professor of Paediatric Haematology at the Department of Paediatrics, talk candidly about their work and how they’re helping the fight against cancer.

Oxford University Professors to lecture on new course in 'Translational Science' at three Brazilian institutions

The Department of Paediatrics at the University of Oxford, has entered into an agreement with three Brazilian Universities, to contribute to the delivery of an undergraduate course in ‘Translational Science’, starting in 2024.

FCDO Minister meets with vaccine researchers

Researchers from the Department of Paediatrics today welcomed the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.

DoP professor named in New Year's Honours list

Matthew Snape, Professor of Paediatrics and Vaccinology at the Oxford Vaccine Group (OVG) before moving to Moderna in August 2022, has been appointed Member of the Most Excellent Order of the British Empire (MBE) for services to Public Health, particularly during COVID-19 while working at the OVG.

Load More